Agrow is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serenade EU approval to extend to bactericide use

EU member states have supported proposals to correct the existing EU registration for Bayer CropScience’s biofungicide, Bacillus subtilis strain QST 713, to include its additional use as a bactericide against fireblight (Erwinia amylovora). Uses as a fungicide and bactericide had been assessed before the active ingredient originally gained EU approval in 2007, but the authorisation listing erroneously omitted the bactericide use. In January 2015, the Netherlands notified the European Commission that the applicant had requested the correction. The change requires publication in the EU Official Journal before coming into force. The product is sold as Serenade for use on grapevines, fruit and vegetables. It was developed by AgraQuest, which was acquired by Bayer in 2012. Assessment of the renewal of the ai’s approval is under way and the existing authorisation has been extended to April 2018 to allow more time for regulatory procedures to be completed.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG022815

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel